Form 4: Recursion Pharmaceuticals Director Blake Borgeson Receives Equity and Option Grants

Blake Borgeson, a Director at Recursion Pharmaceuticals, Inc., was granted 22,016 restricted stock units and options to purchase 44,031 shares of Class A Common Stock as part of the company's Outside Director Compensation Policy.

Summary

• Blake Borgeson, a Director of Recursion Pharmaceuticals, Inc. (RXRX), received a grant of 22,016 shares of Class A Common Stock in the form of restricted stock units (RSUs) on June 18, 2025.
• These RSUs were granted at a price of $0 and will vest on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 Annual Meeting of Stockholders, contingent on his continued service.
• Additionally, Mr. Borgeson was granted stock options to acquire 44,031 shares of Class A Common Stock on June 18, 2025, with an exercise price of $5.11 per share.
• These stock options will vest and become exercisable on the earlier of June 18, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, also subject to his continued service.
• The options have an expiration date of June 18, 2035.
• Following these transactions, Mr. Borgeson directly beneficially owns 7,089,863 shares of Class A Common Stock and 44,031 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The filing indicates a routine, expected compensation event for a director, which is generally a neutral to slightly positive signal as it aligns director interests with shareholders. There are no negative implications.

Positives

• The grants align the director's interests with long-term shareholder value through equity ownership.
• The compensation package reflects standard practice for outside directors, indicating stable corporate governance.

Risks

• The vesting of both the restricted stock units and stock options is subject to the reporting person's continued service to the Issuer.

Future Outlook

The restricted stock units and stock options granted to Director Blake Borgeson are scheduled to vest on the earlier of June 18, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders, contingent on his continued service to Recursion Pharmaceuticals.

Industry Context

This Form 4 filing represents a routine compensation event for an outside director, common across publicly traded companies to align director incentives with long-term company performance and shareholder interests. Such grants are standard practice in the biotechnology and pharmaceutical sectors to attract and retain experienced board members.

Comparison to Industry Standards

• The grant of restricted stock units and stock options to an outside director is a standard component of executive and director compensation packages in the U.S. public market, particularly within the high-growth biotechnology sector.
• The structure of equity-based compensation, including vesting schedules tied to continued service, is consistent with industry benchmarks for attracting and retaining qualified board members.
• No specific comparable companies, projects, or quantitative results are mentioned in the filing to allow for a direct numerical comparison.

Related Party Transactions

• The grant of 22,016 restricted stock units and 44,031 stock options to Blake Borgeson, a Director of Recursion Pharmaceuticals, constitutes a related party transaction as it involves compensation from the company to a member of its board of directors.
• This transaction is explicitly stated to be "automatically granted pursuant to the Issuer's Outside Director Compensation Policy," indicating it is part of a pre-approved compensation framework for related parties.

Stakeholder Impact

• Shareholders: The grants align the director's long-term interests with shareholder value creation, as the value of the equity is tied to the company's stock performance. This represents a standard, expected cost of corporate governance.
• Employees: No direct impact on employees is indicated by this specific director compensation filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• Vesting of 22,016 restricted stock units on the earlier of June 18, 2026, or the day prior to the Issuer's 2026 Annual Meeting of Stockholders.
• Vesting and exercisability of 44,031 stock options on the earlier of June 18, 2026, or the date of the Issuer's 2026 Annual Meeting of Stockholders.

Key Dates

Recommendation

Keywords

Recursion Pharmaceuticals, RXRX, SEC Form 4, Insider Transaction, Director Compensation, Restricted Stock Units, Stock Options, Equity Grant, Blake Borgeson